A Phase 1, Open-label, Multicenter Study of GSK5533524 Alone or in Combination With Other Anti-cancer Agents, in Adult Participants With Selected Advanced Solid Tumors
Latest Information Update: 04 Mar 2026
At a glance
- Drugs GSK 5533524 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GSK
Most Recent Events
- 04 Mar 2026 New trial record